Momenta’s non-invasive drug delivery program explores the role that sugars can play in facilitating the transport of drugs, such as therapeutic proteins, across mucosal membranes which are present in the body in areas such as the lungs and gastrointestinal tract. Most therapeutic proteins, as well as other large macromolecules, can only be introduced into the body through injection. Through our sequencing capabilities, we have discovered that sugars can efficiently transport these drugs across membranes and facilitate their non-invasive delivery. We believe our technology will enable improvements in the non-invasive delivery of a broad range of therapeutic proteins, leading to increased bioavailability, improved safety, and the ability to deliver larger drugs. Our current focus is on the pulmonary delivery of therapeutic proteins, where bioavailability has been a challenge, with a specific focus on interferon beta, erythropoietin, insulin and human growth hormone. We believe our pulmonary delivery has significant advantages over current technologies including the fact that it targets larger drug particles to the upper lung, works with natural sugar formulations and results in greater levels of bioavailability than levels reported by others.